IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has been assigned a $3.00 price target by research analysts at HC Wainwright in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 279.75% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the stock. Maxim Group set a $2.00 price objective on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a report on Friday, February 9th. Zacks Investment Research cut shares of IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $2.53.

Shares of IntelliPharmaCeutics Intl (IPCI) opened at $0.79 on Monday. The stock has a market cap of $23.30, a price-to-earnings ratio of -2.26 and a beta of 1.06. IntelliPharmaCeutics Intl has a fifty-two week low of $0.70 and a fifty-two week high of $2.92.

An institutional investor recently raised its position in IntelliPharmaCeutics Intl stock. Advisor Group Inc. boosted its position in shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) by 57.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,409 shares of the company’s stock after acquiring an additional 17,342 shares during the period. Advisor Group Inc. owned 0.16% of IntelliPharmaCeutics Intl worth $100,000 at the end of the most recent quarter. 3.28% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at

IntelliPharmaCeutics Intl Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with's FREE daily email newsletter.